Do analysts prefer ABP or XAGE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ABP or XAGE more profitable?

Abpro has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Longevity Health -682.67% N/A -261.90%

Do analysts prefer XAGE or PPBT?

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,900.00%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Longevity Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer XAGE or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XAGE or SCNI more profitable?

Scinai Immunotherapeutics has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Company Net Margins Return on Equity Return on Assets Longevity Health -682.67% N/A -261.90% Scinai Immunotherapeutics N/A N/A N/A

Do analysts prefer VBIO or XAGE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate XAGE or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Longevity Health (XAGE) Competitors

$0.28 -0.04 (-11.95%)

As of 08/10/2026 12:35 PM Eastern

Compare

XAGE vs. ABP, PPBT, SCNI, VBIO, and ONCO

Should you buy Longevity Health stock or one of its competitors? Longevity Health's main competitors and comparable companies include Abpro (ABP), Purple Biotech (PPBT), Scinai Immunotherapeutics (SCNI), Valion Bio, Inc. Common Stock (VBIO), and Onconetix (ONCO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Longevity Health compare to Abpro?

Abpro (NASDAQ:ABP) and Longevity Health (NASDAQ:XAGE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Abpro has higher earnings, but lower revenue than Longevity Health. Abpro is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Longevity Health	$1.05M	0.47	-$10.37M	-$4.29	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Abpro's average media sentiment score of 0.00 equaled Longevity Health'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Longevity Health	Neutral

23.3% of Abpro shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 29.0% of Longevity Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abpro has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Longevity Health	-682.67%	N/A	-261.90%

Summary

Longevity Health beats Abpro on 5 of the 9 factors compared between the two stocks.

How does Longevity Health compare to Purple Biotech?

Longevity Health (NASDAQ:XAGE) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Purple Biotech had 2 more articles in the media than Longevity Health. MarketBeat recorded 2 mentions for Purple Biotech and 0 mentions for Longevity Health. Purple Biotech's average media sentiment score of 1.50 beat Longevity Health's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Longevity Health	Neutral
Purple Biotech	Very Positive

Purple Biotech has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Purple Biotech	N/A	-136.79%	-100.38%

Longevity Health has higher revenue and earnings than Purple Biotech. Longevity Health is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.47	-$10.37M	-$4.29	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

Longevity Health has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,900.00%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Longevity Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Purple Biotech beats Longevity Health on 9 of the 15 factors compared between the two stocks.

How does Longevity Health compare to Scinai Immunotherapeutics?

Longevity Health (NASDAQ:XAGE) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Longevity Health has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

Scinai Immunotherapeutics has higher revenue and earnings than Longevity Health. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.47	-$10.37M	-$4.29	N/A
Scinai Immunotherapeutics	$1.31M	0.99	-$8.31M	-$1.06	N/A

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 29.0% of Longevity Health shares are held by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than Longevity Health. MarketBeat recorded 4 mentions for Scinai Immunotherapeutics and 0 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.00 beat Scinai Immunotherapeutics' score of -0.27 indicating that Longevity Health is being referred to more favorably in the media.

Company	Overall Sentiment
Longevity Health	Neutral
Scinai Immunotherapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scinai Immunotherapeutics has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Scinai Immunotherapeutics	N/A	N/A	N/A

Summary

Scinai Immunotherapeutics beats Longevity Health on 10 of the 13 factors compared between the two stocks.

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Longevity Health (NASDAQ:XAGE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Valion Bio, Inc. Common Stock's average media sentiment score of 0.00 equaled Longevity Health'saverage media sentiment score.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Neutral
Longevity Health	Neutral

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	1.53	-$8.88M	-$6.68	N/A
Longevity Health	$1.05M	0.47	-$10.37M	-$4.29	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
Longevity Health	-682.67%	N/A	-261.90%

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 24.2% of Longevity Health shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 29.0% of Longevity Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Longevity Health has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Summary

Valion Bio, Inc. Common Stock beats Longevity Health on 7 of the 12 factors compared between the two stocks.

How does Longevity Health compare to Onconetix?

Longevity Health (NASDAQ:XAGE) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Onconetix had 2 more articles in the media than Longevity Health. MarketBeat recorded 2 mentions for Onconetix and 0 mentions for Longevity Health. Longevity Health's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
Longevity Health	Neutral
Onconetix	Neutral

Longevity Health has a net margin of -682.67% compared to Onconetix's net margin of -1,316.28%. Longevity Health's return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Onconetix	-1,316.28%	-101.08%	-47.34%

Longevity Health has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, indicating that its share price is 169% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 29.0% of Longevity Health shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Longevity Health has higher revenue and earnings than Onconetix. Longevity Health is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05M	0.47	-$10.37M	-$4.29	N/A
Onconetix	$810K	1.26	-$14.03M	$11.40	0.08

Summary

Onconetix beats Longevity Health on 7 of the 13 factors compared between the two stocks.

Get Longevity Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XAGE vs. The Competition

Export

Metric	Longevity Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$499K	$3.70B	$7.01B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.07%
P/E Ratio	-0.07	9.09	269.18	24.72
Price / Sales	0.47	1,262.30	592.48	98.19
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	-0.04	18.15	11.44	6.42
Net Income	-$10.37M	-$13.25M	$3.45B	$347.03M
7 Day Performance	32.08%	3.13%	1.94%	0.71%
1 Month Performance	24.44%	-1.65%	-0.55%	-0.87%
1 Year Performance	-89.27%	61.80%	75.51%	21.94%

Longevity Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XAGE Longevity Health	N/A	$0.28 -11.9%	N/A	-89.6%	$499K	$1.05M	N/A	14	Gap Down
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
PPBT Purple Biotech	3.4173 of 5 stars	$1.45 -3.3%	$30.00 +1,969.0%	-93.0%	$1.35M	N/A	N/A	20
SCNI Scinai Immunotherapeutics	0.3971 of 5 stars	$0.25 -0.1%	N/A	-83.5%	$1.29M	$1.31M	N/A	20	News Coverage Negative News
VBIO Valion Bio, Inc. Common Stock	0.2854 of 5 stars	$0.29 -12.7%	N/A	-90.9%	$1.20M	$780K	N/A	10	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XAGE) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longevity Health (XAGE) Competitors

XAGE vs. ABP, PPBT, SCNI, VBIO, and ONCO

How does Longevity Health compare to Abpro?

Summary

How does Longevity Health compare to Purple Biotech?

Summary

How does Longevity Health compare to Scinai Immunotherapeutics?

Summary

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Summary

How does Longevity Health compare to Onconetix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XAGE vs. The Competition

Longevity Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longevity Health (XAGE) Competitors

XAGE vs. ABP, PPBT, SCNI, VBIO, and ONCO

How does Longevity Health compare to Abpro?

Which has higher earnings & valuation, ABP or XAGE?

Do analysts prefer ABP or XAGE?

Does the media refer more to ABP or XAGE?

Do institutionals & insiders have more ownership in ABP or XAGE?

Is ABP or XAGE more profitable?

Summary

How does Longevity Health compare to Purple Biotech?

Does the media favor XAGE or PPBT?

Is XAGE or PPBT more profitable?

Which has higher valuation & earnings, XAGE or PPBT?

Which has more risk & volatility, XAGE or PPBT?

Do analysts prefer XAGE or PPBT?

Do institutionals and insiders have more ownership in XAGE or PPBT?

Summary

How does Longevity Health compare to Scinai Immunotherapeutics?

Which has more volatility and risk, XAGE or SCNI?

Which has stronger valuation & earnings, XAGE or SCNI?

Do insiders & institutionals hold more shares of XAGE or SCNI?

Does the media refer more to XAGE or SCNI?

Do analysts prefer XAGE or SCNI?

Is XAGE or SCNI more profitable?

Summary

How does Longevity Health compare to Valion Bio, Inc. Common Stock?

Do analysts prefer VBIO or XAGE?

Does the media refer more to VBIO or XAGE?

Which has higher valuation & earnings, VBIO or XAGE?

Is VBIO or XAGE more profitable?

Do institutionals & insiders have more ownership in VBIO or XAGE?

Which has more volatility & risk, VBIO or XAGE?

Summary

How does Longevity Health compare to Onconetix?

Does the media favor XAGE or ONCO?

Is XAGE or ONCO more profitable?

Which has more volatility and risk, XAGE or ONCO?

Do analysts rate XAGE or ONCO?

Do institutionals and insiders believe in XAGE or ONCO?

Which has higher earnings and valuation, XAGE or ONCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XAGE vs. The Competition

Longevity Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools